Literature DB >> 3876325

Trimethoprim sulphamoxole in the treatment of chancroid. Comparison of two single dose treatment regimens with a five day regimen.

J Dylewski, H Nsanze, L D'Costa, L Slaney, A Ronald.   

Abstract

In a prospective blinded study, 135 men with genital ulcers culture positive for Haemophilus ducreyi, were randomized to one of three regimens. Two single dose regimens, either the combination of sulphamoxole 3200 mg/trimethoprim 640 mg or trimethoprim 700 mg alone were compared to a five day regimen of sulphamoxole 800 mg/trimethoprim 160 mg twice daily. All 31 treated with a five day regimen of trimethoprim sulphamoxole healed without further treatment. Of 27 patients treated with the single dose sulphamoxole/trimethoprim regimen, only 21 were cured and of 34 treated with trimethoprim alone, 25 responded. Antibacterial susceptibilities were performed on 31 H. ducreyi isolates. The laboratory susceptibility of these strains to trimethoprim correlated with the clinical response to the single agent. Trimethoprim alone in a dose of 700 mg or the combination of sulphamoxole (3200 mg) and trimethoprim (640 mg) is not satisfactory for the single dose treatment of genital ulcer disease. However, when prescribed for five days, sulphamoxole/trimethoprim is effective and compares favourably with other treatment regimens.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876325     DOI: 10.1093/jac/16.1.103

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Antimicrobial susceptibility of Haemophilus ducreyi.

Authors:  Y Dangor; R C Ballard; S D Miller; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 2.  Treatment of chancroid.

Authors:  Y Dangor; R C Ballard; S D Miller; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

3.  Treating chancroid: summary of studies in southern Africa.

Authors:  R C Ballard; M O Duncan; H G Fehler; Y Dangor; F L Exposto; A S Latif
Journal:  Genitourin Med       Date:  1989-01

4.  Single dose trimethoprim-sulphamethoxazole for treatment of chancroid.

Authors:  B Kumar; G Dawn
Journal:  Genitourin Med       Date:  1995-04

5.  Treating chancroid with enoxacin.

Authors:  W Naamara; D Y Kunimoto; L J D'Costa; J O Ndinya-Achola; H Nsanze; A R Ronald; F A Plummer
Journal:  Genitourin Med       Date:  1988-06

6.  Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya.

Authors:  K S MacDonald; D W Cameron; L D'Costa; J O Ndinya-Achola; F A Plummer; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

7.  In vitro susceptibilities of isolates of Haemophilus ducreyi from Thailand and the United States to currently recommended and newer agents for treatment of chancroid.

Authors:  J S Knapp; A F Back; A F Babst; D Taylor; R J Rice
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  Single-dose ceftriaxone for chancroid.

Authors:  M I Bowmer; H Nsanze; L J D'Costa; J Dylewski; L Fransen; P Piot; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

9.  Correlation between in vitro antimicrobial susceptibilities and beta-lactamase plasmid contents of isolates of Haemophilus ducreyi from the United States.

Authors:  M Motley; S K Sarafian; J S Knapp; A A Zaidi; G Schmid
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.